Inmunómica traslacional en neoplasias hematológicas
University of Michigan–Ann Arbor
Ann Arbor, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Michigan–Ann Arbor (3)
2020
-
A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
Leukemia, Vol. 34, Núm. 12, pp. 3298-3309
2008
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229
2007
-
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
Blood, Vol. 110, Núm. 10, pp. 3557-3560